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EDITORIAL REVIEW
Induction and progression of experimental lupus nephritis:
Exploration of a pathogenetic pathway
Systemic lupus erythematosus is an autoimmune disease in
which the occurrence of immune complex glomerulonephritis is
a prominent manifestation [1]. This disease is characterized by
the formation of antibodies directed against art array of auto-
antigens. The pathogenetic mechanism responsible for lupus
nephritis is still not fully known. Sparsity of well-defined animal
models has hampered research into the pathogenesis of lupus
nephritis, however, mouse strains that spontaneously develop
autoimmunity (such as NZB/W, MLR) constitute widely ac-
cepted models [2]. In these mouse strains, a lupus-like syn-
drome develops spontaneously with a later onset and consider-
able interindividual variability. Therefore, these models are not
easy to manipulate for experimental purposes and their use is
relatively time consuming. With the introduction in 1968 of
experimental murine chronic graft-versus-host disease [3, 4],
the scientific community was provided with an inducible exper-
imental model that has since become a source of information on
the pathogenetic pathways of autoimmunity in general and
lupus nephritis in particular. Together with insights obtained
from other experimental models we now, over two decades
later, have at least some idea of how self-immunity develops.
The purpose of this review is to present current data concerning
the model of chronic graft-versus-host disease in the mouse,
with special attention to autoimmune glomerulonephritis. Anal-
ysis of this model in combination with recent results obtained
with other models has yielded a concise, partially speculative
outline of the pathogenetic pathway.
Graft-versus-host disease and auto-immunity
The administration of foreign lymphoid cells to X-irradiated
recipients or immune immature neonates usually leads to an
acute and rapidly fatal allogeneic disease. Characteristic symp-
toms occurring in both humans and experimental animals
include: dermatitis, diarrhea, lymphoid atrophy, and runting
(wasting) [5—7]. Classically, the induction of a lethal graft-
versus-host reaction by injection of parental lymphocytes into
an Fl-hybrid occurs when the Fl-hybrid and the parent differ
with respect to both class I and class II MHC antigens. This
reaction is usually associated with the activation of donor
allosuppressor/cytotoxic CD8+ anti-Fl T cells [8, 9]. The
administration of relatively low doses of allogeneic lymphoid
cells to an adult host occasionally leads to a more chronic form
of the disease [4]. In certain parent-hybrid combinations, acti-
vation of donor alloanti-class II CD4 + T cells gives rise to a
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chronic graft-versus-host reaction, representing a model of
certain types of autoimmunization [8—10]. The chronic graft-
versus-host reaction is associated with the absence of allocyto-
toxic Lyt2+ anti-Fl T cells [11, 12]. Recipient B-cells are
activated by the anti-allo-class II CD4+ donor T cells, which in
turn leads to a lupus-like autoimmune syndrome [9, 13]. The
graft-versus-host disease induced in the same Fl strain of mice
can be manifested as various forms of connective tissue dis-
ease, depending on the parental donor strain used [14]. Trans-
plantation of a sublethal dose of normal BALB/c spleen cells
into mature (BALB/c x A/Jax)F1 mice, induces glomerulone-
phritis [3]. In this strain combination, the renal lesion is
membranous glomerulonephritis, often accompanied by a se-
vere nephrotic syndrome [3]. When DBAI2 lymphocytes are
transplanted into (C57BL1O x DBA/2)Fl hybrids, a defect in
Lyt2+ anti-B 10 T-cytotoxicity in the DBAI2inoculateunderlies
the development of chronic autoimmunity. In this strain com-
bination this induces a lupus type of nephritis, which is the
subject of the present paper.
Graft-versus-host disease and lupus nephritis
For the induction of chronic graft-versus-host disease, 8- to
10-week-old (C57BL1O x DBA/2)Fl hybrids are used as recip-
ients of DBA/2 donor lymphocytes [15]. Four cell suspensions
containing a mixture of thymus, spleen, and lymph-node donor
cells (the last of these originating from mesenteric, inguinal, and
axillary lymph nodes) are injected intravenously at three to four
day intervals. The recipient mice develop a variety of patho-
logical alterations associated with the formation of autoantibod-
ies [16, 17]. As in human lupus erythematosus, during chronic
graft-versus-host disease auto-antibodies directed against nu-
clear antigens (for example, anti-double-stranded DNA) and
auto-antibodies against erythrocytes are elicited. Albuminuria,
assessed by rocket electrophoresis [18], increases markedly in
the affected animals, causing hypoalbuminemia and frequently
edema; furthermore, creatinine clearance decreases and uremia
develops.
Twelve to fourteen weeks after induction of the disease, the
kidneys show glomerular mesangial, segmental, and diffuse
proliferations as well as membranous nephritis and, in the most
severe cases, global glomerulosclerosis [19]. The majority of
the animals show a proliferative type of glomerular lesion. With
the use of immunofluorescence, deposits of immunoglobulin
and complement are observed in a granular pattern along the
glomerular capillary wall (mostly IgG) and in the mesangium
(1gM and IgG). Electron microscopy reveals the presence of
mesangial and subepithelial electron-dense deposits with vary-
ing degrees of spike formation and incorporation of electron-
dense material in the glomerular basement membrane. Kidneys
of animals with proliferative alterations have electron-dense
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deposits in subendothelial localizations as well. These patho-
logical alterations are characteristic of human lupus nephritis
and have been classified by the World Health Organization
(WHO) [201.
Genetics
In a series of studies on the influence of the genotype on the
susceptibility for renal involvement in murine chronic graft-
versus-host disease, we performed experiments in which we
used congenic mouse strains [21]. When graft-versus-host dis-
ease was induced in (C57BL1O x DBAI2)Fl and (B10.S X
DBAI2)F1 hybrids by injection of DBA/2 lymphocytes, the
autoimmune syndrome as described above developed in all of
the animals. However, renal disease and proteinuria occurred
in all of the (CS7BL1O x DBAI2)Fl hybrids, but only in 54% of
the (Bl0.S x DBAI2)Fl individuals. Morphologic examination
showed that all of the diseased animals of both strains had a
lupus type of glomerulonephritis. We then wanted to know
whether the H-2 haplotype or some other factor, such as
non-H-2 linked genes, determine the susceptibility for renal
involvement in graft-versus-host disease. For these studies, we
produced (BlO x Bl0.S)F1 x DBA/2 mice, determined their
H-2 genotype serologically, and separated them into H2bdand
H2thl groups. These two groups did not differ with respect to
susceptibility to glomerulonephritis in the course of graft-
versus-host disease, which indicates that H-2 is not the decisive
genetic factor.
Supposedly, factors not linked with H-2 exert a major influ-
ence on susceptibility to graft-versus-host disease-related renal
disease, as shown by these studies. Incidental fixation of
non-H-2 genes of the donor strain or genetic mutation or
infection with bacteria or viruses may be responsible for
non-H-2 differences between congenic strains [22—24]. Alterna-
tively, the differences observed in our study could be due to the
action of polymorphic non-H-2 genes. The influence of genetics
on susceptibility to nephritis and systemic lupus erythematosus
is a subject of persisting interest in the literature. Numerous
genetic studies and reviews done in human populations as well
as various murine models of human autoimmune processes
have been reported [25—41]. The search for specific genes
controlling systemic lupus erythematosus has yielded a consid-
erable amount of evidence that a role is played by MHC-
encoded regions, although non-MHC genes are in all probability
involved as well [42]. Fewer data pointing to genetic control of
renal involvement in lupus erythematosus are available. Studies
on experimental models of glomerulonephritis, making use of
genetically well-defined animals, have shown differences in
susceptibility to the induction of glomerular lesions in response
to identical challenges [31, 321. The work done by Gavaichin
and coworkers on lupus-prone (SWR x NZB)Fl indicated that
auto-antibodies encoded by genes of normal non-autoimmune
mice can become expressed if the latter interact with genes of
an abnormal autoimmune mouse [33]. This supports the con-
cept that a multi-step, multi-gene process underlies the de-
velopment of autoinimune disease [33]. In autoimmune (NZB X
NZW)F1 mice, a gene or genes in the NZW background
accelerate and intensify the mild lupus-like autoimmunity of
NZB mice [36—38]. An MHC-regulated response was found in
mercuric chloride-induced autoimmune nephritis in rats, al-
though one or two genes at unlinked loci are also obligatory
[41]. Thus, in these models genes at loci outside the MHC also
seem to play a role in determining whether synthesis of patho-
genic autoantibodies can proceed. This is consistent with our
findings, which confirm an influence of non-MHC factors on
susceptibility to autoimmune nephritis in murine chronic graft-
versus-host disease. Further investigation of the genetic control
of experimental graft-versus-host disease-related glomerulone-
phritis is now possible because of the availability of the recently
developed recombinant congenic strains, which allows study of
the role of individual non-H-2 genes [43].
Nephritogenic auto-antibodies
Transfer of lymphocytes derived from DBA/2 donor mice
into (CS7BL1O x DBA/2)F1 hybrids invariably leads to autoim-
mune disease and lupus-like glomerulonephritis. The question
as to which autoantibodies play a pathogenetic role in autoim-
mune glomerulonephritis in general has not been unequivocally
resolved. However, work done in the last few decades has
resulted in the identification of several groups of antibodies
occurring in human or experimental autoimmune-related ne-
phritis. In sera and eluates of glomeruli from mice suffering
from chronic graft-versus-host disease, we found antibodies
directed against nuclear antigens (ANA), against glomerular
basement membrane (GBM), and against RTE, a pool of renal
tubular epithelial antigens [44, 45]. Antiglomerular basement
membrane antibodies were further characterized as being di-
rected against type IV collagen and laminin, and we recently
found activity against the o1-3 galactosyl residue of the laminin
molecule (unpublished observations). Anti-RTE antibodies
were directed against the glomerular enzyme dipeptidyl pepti-
dase type IV (DPPIV, gp9O), and against a 160 kD RTE
component described by Rolink, Radaszkiewicz and Melchers
[46, 47]. Further studies employing elution of isolated glomeruli
and transfer experiments showed that the glomerular enzyme
dipeptidyl peptidase type IV and the glomerular basement
membrane component laminin are prominent auto-antigens in
this model [451. Concerning the role of antinuclear antibodies,
some exciting new insights have been developed over the last
years, as discussed recently by Brinkman and colleagues [48].
In short, their studies have shown that antinuclear antibodies
and, more specifically anti-DNA antibodies, may bind to the
glomerular basement membrane (particularly to heparan sul-
fate) after combination with DNA-histone particles. Histones
are known to have high affinity for the glomerular basement
membrane [49]. Histone-GBM interaction and not anti-DNA
cross reactivity is thought to be responsible for binding of
anti-DNA to glomerular basement membrane [48]. In our own
studies, transfer of anti-nuclear antibodies from sera of diseased
mice into naive recipients did not lead to glomerular binding or
renal disease; thus, the role of antinuclear antibodies in this
model and in human lupus nephritis requires further study [45].
Glomerulonephritis
According to the studies cited above, it is conceivable that
antibodies directed against dipeptidyl peptidase type IV and
against laminin play a pathogenic role in this model. These
antibodies occur, together with complement, in the glomeruli of
diseased animals, and this is related to an abnormal loss of
serum albumin into the urine. A relationship between humoral
autoimmunity and different forms of glomerulonephritis is well
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established [50]. The exact mechanisms responsible for the
relationship between the binding of auto-antibodies in the
glomeruli and the development of proteinuria have been the
subject of a number of reviews, and will not be extensively dealt
with here. Briefly, alterations in both the charge barrier and the
size barrier have been suggested as the cause of proteinuria.
The developmental mechanism underlying various renal dis-
eases has been related to a decrease in the number of anionic
sites in the glomerular basement membrane [SI], which may be
induced by a decrease in negatively-charged glomerular base-
ment membrane heparan sulfate proteoglycans [52]. In addi-
tion, binding of anti-dipeptidyl peptidase type IV auto-antibod-
ies leads to a rearrangement of this molecule on the glomerular
epithelial cell surface. Dipeptidyl peptidase type IV functions as
an adhesion molecule on the glomerular epithelial cell surface,
and its rearrangement may in itself be related to an alteration in
the functioning of these cells and increased permeability of the
glomerular capillary wall [53, 54]. The binding of auto-antibod-
ies to molecules present in the glomerular capillary wall can
lead to the formation of large, electron-dense aggregates by
several mechanisms. These mechanisms have been discussed in
detail elsewhere [55]. Briefly, linear binding of antibasement
membrane antibodies may be followed by rearrangement and
condensation of the antigen-antibody complexes and formation
of dense aggregates [56—59]. Alternatively, combination of
antibodies with cell-binding epitopes of basement membrane
components or basement membrane precursor molecules oc-
curring on the surface of epithelial and endothelial cells may be
followed by shedding and condensation of the complexes. A
third mechanisms may occur in passive models where several
specificities of antibodies are used, and in situations of poly-
clonal or restricted polyclonal B-cell stimulation, as in our
model of chronic graft-versus-host disease [44, 60]. In such
cases, binding of anti-GBM antibodies may precede binding of
antibodies directed against antigens of epithelial cells, such as
dipeptidyl peptidase type IV, followed by dense aggregate
formation after capping and shedding of the latter. In these
lupus mice, the formation of subepithelial electron-dense im-
mune aggregates somehow triggers irregular thickening of the
glomerular basement membrane and the formation of spikes,
resulting in a membranous type of nephropathy and, eventually,
glomerulosclerosis.
Glomeruloscierosis
The question as to what the glomerulosclerotic lesion actually
consists of can now be partially answered on the basis of
recently obtained data on the biochemical composition of the
extracellular matrix. Glomerulosclerosis is characterized by the
glomerular accumulation of extracellular matrix synthesized by
glomerular cells [61—65]. In our model of chronic graft-versus-
host disease—starting in the tenth week after the transfer of
lymphocytes—the Fl mice develop glomerulosclerosis leading
to end-stage renal failure. During the course of the development
of glomerulosclerosis in this model, we found abnormal
amounts of extracellular matrix molecules, including fibronec-
tin, laminin, and collagen of types I, III, IV, and VI [66].
Collagen types I and III are the so-called 'interstitial collagens,'
and their presence in the sclerotic glomeruli indicates either a
phenotype-switch of glomerular cells, or an influx of interstitial
cells into the damaged glomeruli [63, 70]. Interstitial collagens.
and especially collagen type III, are resistant to enzymatic
degradation by collagen IV-specific neutral metalloproteinases
released by glomerular cells, which means that their presence
may contribute to glomerulosclerosis [71—73].
The abnormal presence of extracellular matrix components is
related to elevated steady-state mRNA levels in the kidneys and
isolated glomeruli from these mice, indicating an abnormal
synthesis regulated at the transcriptional level [68]. It is now
known that abnormalities in the interactions between cells,
adhesion molecules, and matrix proteins that may occur during
glomerulonephritis can cause excessive and disorganized bio-
genesis of extracellular matrix proteins [74-78]. This has been
shown in a number of in vitro studies, as well as in experimental
counterparts of human disease. In most of the animal models
used, glomerular injury is caused immunologically by antibod-
ies directed against antigens occurring either on mesangial or
epithelial cells or in the glomerular extracellular matrix [re-
viewed in 55]. Besides the graft-versus-host model, our own
work has involved a number of animal models in which,
depending upon the genetic makeup of the animal, an autoim-
mune reaction may lead to the appearance of nephritogenic
auto-antibodies. Upon binding in the glomerulus, these antibod-
ies elicit expansion of the extracellular matrix, which is re-
flected morphologically by a widening of the mesangial area and
thickening of the glomerular basement membrane, and in some
cases eventual glomerulosclerosis [45, 58, 60, 69, 79—83]. Inter-
estingly, we and others have found that, although indistinguish-
able by routine histologic methods, the molecular composition
of the glomerulosclerotic lesions in experimental animals and
humans differs between the models or diseases studied [61, 66,
70, 82, 84—87]. As indicated above, in our model as in others,
studies on the steady state levels of mRNA encoding for
extracellular molecules suggested that the increased production
of extracellular matrix leading to glomerulosclerosis is regu-
lated at the transcriptional level [68, 88, 89]. It is noteworthy
that Fogel et al recently reported that increased synthesis of
extracellular matrix did not occur during glomerular basement
membrane expansion in passive Heymann nephritis [90]. This
suggests that matrix expansion in basement membrane thicken-
ing and spike formation represents a process which differs
fundamentally from matrix expansion in glomerulosclerosis.
Similar studies in diabetes mellitus have shown that capillary
basement membrane thickening may depend more strongly on
reduced basement membrane degradation than on increased
synthesis of basement membrane components [91]. Transcrip-
tion of sequences encoding for extracellular matrix molecules is
regulated by DNA-binding proteins, as recently shown for
collagen type IV by Killen and coworkers [92], and is further
influenced by cytokines. It is currently believed that cytokines
determine not only the degree of extracellular matrix expan-
sion, but also the exact biochemical composition of the lesions.
On these grounds we shall briefly consider recent developments
concerning the central role of cytokines in these processes.
The role of cytokines
The production of extracellular matrix is regulated at least
partially via the action of cytokines. Much work is now being
done on this subject, and several cytokines have been found to
play a role in the regulation of the extracellular matrix metab-
olism of glomerular cells. The cytokines involved may be
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produced by lymphocytes, monocytes, and macrophages resid-
ing outside the kidney, or in the renal tissue. Thus, they exert
their influence in an endocrine or a paracrine fashion, respec-
tively. Furthermore, glomerular epithelial, endothelial, and
mesangial cells can produce cytokines functioning in a para-
crine or autocrine way. Through their action, cytokines regulate
the increased production of extracellular matrix triggered by
glomerular cell damage, and intraglomerular coagulation. More-
over, intraglomerular inflammation and cytokine release can
also presumably initiate increased collagen synthesis in the
extraglomerular compartment, and thus mediate the genesis of
interstitial fibrosis [93]. Accumulation of extracellular matrix
can be further enhanced by the ability of cytokines to suppress
the expression of proteases and stimulate the expression of
protease inhibitors [94, 89]. Evidence for a role of cytokines in
the modulation of extracellular matrix production by glomerular
cells has been obtained for transforming growth factor (TGF)-
/31, which regulates both cell turnover and extracellular matrix
synthesis [88, 89, 95—97], as well as for epidermal growth factor
[98]. Other growth factors implicated in the progression of
glomerular disease are interleukin-l (IL-l), possibly via the
activation of IL-6 [99—101], platelet-derived growth factor
(PDGF), tumor necrosis factor (TNF) [100, 102], and other
cytokines, such as gamma-interferon (IFN). An interesting
recent study done in transgenic mice showed that high levels of
circulating growth hormone lead to a disproportionate increase
in glomerular cellularity and volume, and glomerulosclerosis
[103]. In rats with renal ablation, growth hormone deficiency
protects against progressive chronic renal failure and glomeru-
losclerosis [104].
Besides the regulation of extracellular matrix, cytokines
influence intraglomerular fibrin deposition and coagulation,
another hallmark of glomerular sclerosis. The role of TNF and
IL-i in the activation of clotting pathways on endothelial cell
surfaces has recently been outlined [105—1 121. Moreover, cy-
tokines such as IL- 1 and TNF may themselves render endothe-
hal cells more susceptible to injury [113]. Furthermore, cytok-
ines stimulate glomerular cells such as endothelial cells to
synthesize and secrete a variety of other cytokines that may be
involved in extracellular matrix metabolism, including IL-l and
IL-6 [106]. Cytokine-induced expression of adhesion molecules
such as ICAM-l by endothelial cells of intrarenal vessels plays
an essential role in the adhesion of inflammatory cells in the
kidney [114, 115]. Adhesion components may also function in a
dual capacity as adhesion and signalling molecules, thus medi-
ating the local activation of inflammatory cells upon adhesion
[116]. Cytokine stimulation can upregulate both MHC class II
and ICAM-l expression by mesangial cells, which can play a
pivotal role in initiating and directing renal injury in immune-
mediated nephritis [117]. And, finally, cytokines play a direct
role in the genesis of increased vascular permeability [reviewed
in 105], which might well contribute to the development of
proteinuria.
Hemodynamic factors
In the development of glomeruloscierosis, hemodynamic
factors play a key role. Brenner, Meyer and Hostetter put
forward the hyperfiltration theory [1181, attributing the genesis
of sclerosis to overloading in the glomeruli due to a functional
decrease in nephrons [119, 120] and protein overload [121].
Thickening of the glomerular capillary wall and expansion of
the mesangial matrix lead to narrowing of the capillary lumen
and a decrease in the filtration area. This in turn would give rise
to increased glomerular pressure and flow, eventually leading to
glomerular cell injury. Activated and damaged glomerular cells
may again produce and release cytokines, which could further
mediate extracellular matrix gene transcription. Endothelial
damage leads to the exposure of extracellular matrix, to which
platelets may bind via matrix receptors such as /31 and /33
integrins, including the a6/3l laminin receptor, the a5f31 fi-
bronectin receptor, and the a2/3l collagen/laminin receptor
[122, 123]. Activation of the blood coagulation cascade leads to
microthrombosis, and hyalinosis and formation of microaneu-
rysms attributable to the hemodynamic alterations can be
observed as well. These events further decrease the filtration
area and the process continues, finally leading to nephron loss
and deterioration of renal function. Indeed, hemodynamic
changes, such as increased shear stress or turbulent flow, have
been shown to be able to induce endothelial damage [124, 125].
The possible mechanisms underlying the response of endothe-
hal cells to damage have been the subject of extensive research,
and have been reviewed elsewhere [105, 126—128]. However,
although the association between the development of protein-
uria and glomerulosclerosis on the one hand and increased
glomerular flow rates and pressures on the other has been
shown in a number of experiments [129—133], the causal rela-
tionship between these factors is still subject to discussion.
Interstitial damage
With increasing glomerular sclerosis and nephron loss, tubu-
lar atrophy is observed throughout the renal tissue of (C57BLZO
x DBA/2)Fl mice suffering from chronic graft-versus-host
disease. The deteriorating tubuli show collapse with a wrinkled
and thickened basement membrane, and the tubular epithehial
cells show flattening and degeneration. Protein casts are abun-
dantly present. Areas with atrophic tubuli may be intermingled
with hypertrophied and dilated tubules, a combination which
has been related to the fine granularity observed on gross
examination. The areas of tubular atrophy show interstitial
fibrosis and often inflammatory infiltrate.
The interstitial process leading to fibrosis is a final common
pathway leading to most forms of end-stage kidney disease, and
its importance has been partially underscored in the literature
[134]. However, a number of morphometric studies on biopsy
specimens from patients with glomerular dysfunction have
shown that a declining glomerular filtration rate correlates
better with progressive changes in the interstitial architecture
than with morphologic alterations in the glomerWus [134—138].
This might be explained by the finding that the interstitial
fibrosis itself damages the postglomerular capillary network,
leading to a further decrease of the glomerular filtration rate
[139]. Several other theories have also been put forward to
explain why interstitial damage would affect glomerular func-
tion, and these theories have been extensively discussed else-
where [134].
Much has been made clear by research done during the last
decade on the mechanisms playing a role in the progression of
interstitial damage. Tubular atrophy is related to the occurrence
of interstitial lymphocytes, and cell-mediated inflammatory
events govern the further development of the chronic interstitial
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lesion. These mechanisms have been reviewed elsewhere and
will not be discussed in detail here [140, 141]. In short, chronic
interstitial infiltrates are composed mainly of T lymphocytes
and macrophages [142, 143], and both helper and effector T
cells produce cytokines that regulate the homeostasis of extra-
cellular matrix in tubular epithelium and fibroblasts [140, 144].
Not only interstitially-located inflammatory cells, but also in-
terstitial fibroblasts can be stimulated by cytokines produced by
inflammatory cells present in the injured glomerulus [93]. It is
reasonable to assume that these mechanisms play an essential
role in the perpetuation of interstitial injury and fibrosis and
lead to the interstitial scarring typically observed in mice
suffering from chronic graft-versus-host disease-related glomer-
ulonephritis.
Clinical implications
The insights into the pathogenetic pathway of experimental
lupus nephritis presented above are not only of academic
interest but do in fact open up possibilities for therapeutic
intervention at several points in the disease. Concerning our
experimental model, methods of prophylaxis and treatment of
the underlying graft-versus-host disease itself have been re-
viewed recently [145] and will not be dealt with here. The
genetic cloning of cell surface proteins and growth factors will
provide new insights into the complex dysregulation of lympho-
cytes that characterizes the pathogenesis of autoimmunity. At
the basic immunologic level, interference with idiotype-anti-
idiotype interaction is currently under study, Suppression of
adhesion molecules mediating the influx, adhesion and migra-
tion of inflammatory cells may reduce tissue damage [146].
Interference of adhesion molecule-ligand interaction by mono-
clonal antibodies can possibly delay or reverse deleterious
immunologic processes in the kidney. This has already been
shown in vivo for renal allograft rejection, in which monoclonal
antibodies to ICAM- 1 (CD54) inhibit the action of infiltrating
CD3 positive lymphocytes. These lymphocytes are believed to
lyse proximal tubular cells through ICAM-1-mediated interac-
tion [114, 115, 147]. Based on findings in experimental models
of focal and segmental glomeruloscierosis and the recognition
of the role of hemodynamic factors, therapeutic strategies have
been developed involving such measures as dietary protein
restriction, angiotensin converting enzyme inhibition, and low-
ering of lipids, as was recently summarized elsewhere [73].
Concerning the pathobiochemistry of extracellular matrix, ex-
pectations are now certainly high with respect to the emergence
of new therapeutic strategies as the network of cytokine regu-
lation of matrix homeostasis is unravelled. Transgenic mice are
providing much information about the pathophysiological role
of cytokines, and the availability of recombinant cytokines
allows precise study of the effects on certain cell types both in
vitro and in vivo. Already, promising results have been ob-
tained in a recent study by Border and coworkers done in an
experimental model in which the increased production of gb-
merular extracellular matrix was suppressed by administration
of anti-TGFJ31 [88].
Concluding remarks
In this review, we have attempted to provide the reader with
an update of experimental chronic graft-versus-host disease in
mice as a model for lupus nephritis. For reasons of brevity, we
have not reviewed basic information on the structure-function
relationship of the glomerulus and the biochemistry of the
extracellular matrix. We may refer the reader to recently
published excellent reviews on these topics by Kanwar et al
[1481 and by Abrahamson [149]. Together with progress in other
animal models reviewed elsewhere [55], the above-mentioned
observations on experimental murine chronic graft-versus-host
disease and related models of immune-mediated glomerulone-
phritis have led to a better understanding of the pathogenetic
avenue of lupus nephritis, as summarized in Figure 1. As
outlined above, the information mentioned in the tentative
scheme represented in Figure 1 is based partly on our own
observations, partly on those of others and partly on specula-
tion.
However exciting these insights may be, much remains
unclear about the pathogenetic mechanisms governing lupus
nephritis. For most therapeutic implications, long-term studies
on the effect on the progression of renal disease are still needed.
Further experimental and clinical studies are indicated to
increase our comprehension of these processes, so that more
effective preventive and therapeutic measures can be developed
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Fig. 1. Schematic representation of tentative
mechanisms constituting the pathogenetic
pathway of experimental lupus nephritis
discussed in the text.
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for patients suffering from lupus nephritis. Although experimen-
tal chronic graft-versus-host disease has been a fruitful source
of knowledge since its introduction, it is our firm belief that the
major spinoff of this model is yet to come.
JAN A. BRUIJN, ELINE C. BERGIJK, EMILE DE HEER,
GERT JAN FLEUREN, and PHILIP J. HOEDEMAEKER
Leiden, The Netherlands
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